Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07089121 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Descartes-08 for Children, Adolescents, and Young Adults With Autoimmune Disorders

StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study sites: 2 to 3v6
  2. Start date: Mar 12, 2026 to Jan 14, 2026 Site contacts updated at 1 of 2 sitesv5 Show 1 more changeShow less
    • Site contacts updated at 1 of 2 sites
  3. Primary completion date: Dec 2026 to Dec 2027 Study sites: 1 to 2 · Completion date: Dec 2026 to Dec 2028 · Start date changed from estimate of Jan 2026 to Mar 12, 2026v4 Show 3 more changesShow less
    • Study sites: 1 to 2
    • Completion date: Dec 2026 to Dec 2028
    • Start date changed from estimate of Jan 2026 to Mar 12, 2026
  4. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 1 · Start date: Dec 2025 to Jan 2026v3 Show 2 more changesShow less
    • Study sites: 0 to 1
    • Start date: Dec 2025 to Jan 2026
  5. Study title shortened, about 10 wordsv2 See this version in full on ClinicalTrials.gov ↗
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Safety, tolerability and efficacy of Descarte-08 in children, adolescents and young adults with childhood-onset systemic lupus erythematosus, ANCA-associated vasculitis, juvenile myasthenia gravis, and juvenile dermatomyositis
Trial Details
NCT Number NCT07089121
Lead Sponsor Cartesian Therapeutics
Conditions Childhood-onset Systemic Lupus Erythematous, ANCA-Associated Vasculitis (AAV), Juvenile Myasthenia Gravis, Juvenile Dermatomyositis
Enrollment 50 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov